168 results on '"Pilla, Lorenzo"'
Search Results
2. Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study
3. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort
4. Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series
5. Abstract PR06: CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study
6. Safety, Efficacy, and Biomarker Results of a Phase 1b/2 Study Combining the CD40 Agonist Mitazalimab with mFOLFIRINOX in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC); Results of the OPTIMIZE-1 Trial
7. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
8. Supplementary Table 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
9. Supplementary Table 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
10. Supplementary Figure 4 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
11. Supplementary Figure 3 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
12. Supplementary Figure Legend from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
13. Supplementary Figure 5 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
14. Supplementary Figure 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
15. Supplementary Figure 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
16. Supplementary Figure 1 from Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-α Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors
17. MSI colorectal cancer, all you need to know
18. “Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014
19. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
20. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response
21. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy
22. Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients
23. Vaccination therapy in prostate cancer
24. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients
25. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
26. Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects
27. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes
28. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
29. Update on vaccines for melanoma patients
30. Altered peptide ligands of tumor T-cell epitopes
31. Vaccination: role in metastatic melanoma
32. IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells
33. Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings
34. Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges
35. Methods for improving the immunogenicity and efficacy of cancer vaccines
36. Transarterial Chemoembolization with Drug-eluting Beads Preloaded with Irinotecan as a First-Line Approach in Uveal Melanoma Liver Metastases: Tumor Response and Predictive Value of Diffusion-weighted MR Imaging in Five Patients
37. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
38. Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study
39. A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma
40. Expression of PD-L1 and NY-ESO-1 in early and advanced triple-negative breast cancer.
41. Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.
42. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
43. Abstract A89: Loss of HLA molecules as melanoma resistance mechanism in immune checkpoint blockade therapy.
44. Abstract LB-320: Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer.
45. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes
46. Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
47. Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.
48. The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases.
49. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy
50. Autologous Versus Allogeneic Cell-Based Vaccines?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.